RxDoctor Payments DataLook up a doctor →

Amitkumar Patel, MD

Nephrology · Cleveland, OHNPI 1114128758

Payments from drug & device makers

$69,864in general payments, 2019–2025

Across 515 payments — averaging $135.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$63K
  • Amgen$1K
  • Bayer$737
  • OPKO Pharmaceuticals, LLC$702
  • Novartis$694
  • Otsuka America Pharmaceutical, Inc.$503
  • plus $3K from 35 others

What the payments were for

  • Speaking & faculty fees$58,00083%
  • Travel & lodging$1,1642%
  • Food & beverage$10,30415%
  • Education$3971%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,864 in reported general payments places this provider in the 90th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$386,359
Medicare patients
628
Services billed
3,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol476$478,435
JynarqueTolvaptan13$251,027
LokelmaSodium Zirconium Cyclosilicate61$60,869
KerendiaFinerenone50$49,575
JardianceEmpagliflozin37$48,719
RayaldeeCalcifediol24$31,467
EntrestoSacubitril/Valsartan17$13,874
Calcitriol603$13,778
Sevelamer Carbonate53$8,021
Cinacalcet Hcl18$6,221
Torsemide193$5,515
Allopurinol380$4,861
Febuxostat45$3,907
Calcium Acetate60$2,934
Losartan Potassium291$2,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$62,855$539,304537 claims
Otsuka America Pharmaceutical, Inc.Jynarque$503$251,02713 claims
BayerKerendia$737$49,57550 claims
Boehringer IngelheimJardiance$192$48,71937 claims
OPKO Pharmaceuticals, LLCRayaldee$702$31,46724 claims
NovartisEntresto$694$13,87417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 nephrology providers in Ohio.

Other nephrology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →